AMT Medical Raises $25M for Sutureless Coronary Bypass Tech

AMT Medical, a Netherlands-based clinical-stage medtech company, underwent a $25 million Series B financing round that was led by Bender Analytical Holding (BAH).

This funding, according to AMT, will speed development of its ELANA heart bypass system. This minimally invasive solution is designed to replace traditional open-heart bypass surgery with the aim of leading to robot-assisted keyhole surgery compatible with well-known surgical robots.

ELANA lets surgeons perform coronary artery bypass grafting (CABG) with arterial (instead of venous) bypass grafts. It does so through small chest incisions without stopping the heart or using a heart-lung machine—this removes stroke risks and other complications, and reduces post-op recovery times.

The technology contrasts conventional methods requiring sternotomy, complex suturing, and long recovery times. ELANA further aims to reduce costs related to CABG procedures.

The sutureless anastomosis technique uses a clip and excimer laser to connect blood vessels without manual suturing. This way, surgeons can achieve precise, rapid, standardized, and reproducible graft integration.

AMT said the system achieves more than 50% cost reduction, when used in a robotic setting. This comes from shorter operating times, reduced hospital stays, fewer complications, and quicker surgeon mastery.

After the financing round, the capital will drive a number of initiatives for AMT. One is completing a European first-in-human trial evaluating the system during still open chest CABG procedures with a beating heart. Trial results are expected to publish toward the end of the year.

With the data, AMT plans to gain CE marking by 2026 for use during open CABG procedures through sternotomy or a minimally invasive thoracotomy. Clinical trials in the U.S. will also be started in open and robotic setting.

“This financing validates our mission to make open-heart bypass obsolete. By enabling same-day discharge bypass procedures, we’re not just improving outcomes—we’re redefining cardiovascular care,” said AMT Medical co-founder and CEO Rutger Tulleken.